Australia Legal Cannabis Market Size & Forecast to 2035

Market Overview & Executive Summary

Australia's legal cannabis economy has moved decisively past its policy-formation phase into a commercial scale-up anchored in pharmaceutical-grade manufacturing, domestic cultivation and export. Our proprietary primary research programme, built on 340 structured interviews with licensed cultivators, GMP manufacturers, importers, prescribing clinicians and dispensing pharmacists, values the Australia legal cannabis market at USD 879.6 million in 2025, rising to USD 3,012.4 million by 2035 at a 13.1% CAGR (2026–2035).

The category is not one market. Three demand pools behave differently and must be modelled separately:

• Medical-use products drive roughly three-quarters of total value, ordered principally through the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS-B) and Authorised Prescriber (AP) pathways rather than through standard Australian Register of Therapeutic Goods (ARTG) registration.
• Industrial and nutraceutical hemp supplies a mature, lower-margin revenue stream built on fibre, seed, food and low-THC cannabidiol extract applications.
• Personal adult-use, lawful only within the Australian Capital Territory, contributes a small but symbolically important share and remains constrained because retail sale, gifting and seed transfer are prohibited.

Headline Findings

• Medical applications captured 76.4% of 2025 revenue, confirming clinical demand as the commercial engine of the market.
• Hemp-derived inputs led by source with a 54.1% revenue share; marijuana flower, oil and tinctures accounted for the balance.
• CBD-dominant derivatives represented 56.1% of derivative revenue, with THC-dominant and minor-cannabinoid formats making up the remainder.
• Supply-side capacity is still consolidating: as of December 2025, 39 entities held approved medicinal cannabis cultivation and production status, 22 were permitted to manufacture, and 36 held import licences.
• Since federal legalisation in 2016, more than 3.6 million medicinal cannabis prescriptions have been issued in Australia, and patient spending exceeded USD 402 million in the first half of 2024 alone — with unit volumes roughly four times the level recorded in the first half of 2022.

Market Character

The market is best described as a regulated pharmaceutical vertical with an agricultural upstream. Value is concentrated downstream, in finished dosage forms and dispensing, while cultivation remains fragmented and licences are geographically dispersed across every mainland state. That asymmetry shapes pricing power, margin structure and consolidation logic across the forecast period.

Market Size & Forecast Architecture

Our base-case model anchors on 2025 revenue of USD 879.6 million and applies a 13.1% CAGR through 2035, with growth weighted toward 2027–2032 as domestic flower supply matures and prescriber adoption broadens beyond early-adopter clinicians.

Scenario Framework

Volume Dynamics

Revenue growth is outpacing unit growth in the early forecast years because average realised price per gram is compressing as domestic supply displaces imported flower. Dried flower has become the dominant formulation by patient preference, favoured for faster onset in chronic pain, anxiety and insomnia, while oils, capsules and oral sprays retain a loyal long-duration cohort. The revenue mix therefore shifts gradually from extract-led to flower-led, then rebalances as higher-margin specialised formulations return to prominence after 2030.

Key Growth Drivers

Therapeutic Acceptance and Prescriber Confidence

Clinician willingness to prescribe is the single largest swing factor. TGA-approved access pathways and the Authorised Prescriber scheme have shortened approval cycles from weeks to days, and prescriber numbers continue to grow. Chronic pain remains the most frequently cited indication, followed by anxiety, sleep disorders, cancer-related symptoms, epilepsy and multiple sclerosis spasticity.

Unmet Clinical Need

Australia carries a heavy chronic disease burden, with more than three million people estimated to live with persistent pain. Where conventional analgesics deliver limited relief or carry dependence risk, cannabinoid-based therapy becomes a credible alternative — particularly in palliative care and oncology supportive treatment.

Telehealth Distribution

Online clinics have removed geography as a constraint. Patients in rural and remote areas now access cannabis-aware clinicians without travel, and many platforms bundle consultation, prescription and product fulfilment into a single workflow. This channel is now the primary patient acquisition route for most licensed producers.

Domestic Cultivation Scale-Up

Locally produced dried flower volumes have risen sharply since 2021, supported by modular glasshouse systems, precision climate control and hydroponic cultivation. Domestic supply reduces import dependence, shortens lead times and lowers landed cost per gram.

Export Orientation

Australia was among the first jurisdictions globally to legalise medicinal cannabis exports and remains a net exporter of GMP-certified product, with New Zealand, the United Kingdom and Germany as principal destinations. Export licensing provides producers with a demand buffer against domestic pricing pressure.

Restraints and Market Challenges

• Narrow registered product base. Only two cannabis-based medicines are registered on the ARTG, and the vast majority of supply moves through unapproved-goods pathways that remain administratively intensive.
• Regulatory fragmentation. Eight jurisdictions operate distinct rules on possession, cultivation and permissible use, raising national compliance costs and complicating brand-level marketing.
• Cost to patient. The 10% goods and services tax applies to medicinal cannabis sales, and the absence of broad public reimbursement leaves patients bearing nearly the full cost.
• Sustained import reliance in finished formats. Despite cultivation growth, a meaningful share of finished flower continues to be imported, exposing the market to freight, currency and quality-release delays.
• Banking and payment friction. De-risking by some financial institutions raises transaction costs across the value chain.
• Stigma and clinical scepticism. Evidence gaps in several indications slow mainstream integration, even as real-world data accumulates.
• Policy uncertainty on adult-use. Repeated legislative attempts across Victoria, New South Wales and Western Australia have not converted into national reform, deferring any material recreational revenue.

Segment Dynamics: Source, Derivative and End-Use

Source Segmentation

Hemp's leading position rests on permissive low-THC cultivation rules and a broad application set spanning pharmaceuticals, nutraceuticals, textiles and food. Marijuana-derived revenue is more concentrated but carries materially higher revenue per gram, and its share is set to strengthen as medical flower volumes expand.

Derivative Segmentation

CBD holds the largest derivative share at 56.1%, reflecting strong clinical interest in non-intoxicating therapy and a preference among patients and prescribers for formulations without psychoactive burden. THC-dominant derivatives follow, with the remainder accounted for by minor cannabinoids, terpene-rich full-spectrum extracts and specialised blends.

End-Use Segmentation

Within the medical pool, chronic pain alone accounts for the largest single share of prescription volume. Cancer-related symptom management, anxiety, epilepsy and PTSD form the balance, with product differentiation increasingly driven by cannabinoid ratio, terpene profile and delivery format rather than by brand alone.

Import/Export & Supplier Dynamics

Australia operates a dual-licence framework: a medicinal cannabis licence for cultivation, production and manufacture, supported by site-level permits governing volume and THC category, plus separate import and export licences and permits for narcotic and psychotropic substances. Crucially, the 2021 single-licence reform removed fixed expiry dates, reducing renewal risk for long-horizon capital investment.

Supply-Side Capacity Snapshot

• 39 entities approved for cultivation and production activity
• 38 permitted to cultivate and produce
• 22 permitted to manufacture
• 23 licensed medicinal cannabis product manufacturers
• 36 licensed importers

Trade Flow Structure

Supplier Leverage Assessment

Suppliers of genetics, controlled-environment cultivation systems and GMP extraction equipment hold moderate leverage, driven by technical differentiation. Importers of finished flower face eroding leverage as domestic yields rise. Licensed manufacturing capacity is the genuine bottleneck: only 22 of 39 approved entities may manufacture, which concentrates downstream pricing power in a small cohort and creates a durable advantage for vertically integrated operators. Every report is refreshed to the date of purchase, so licence counts and capacity figures reflect the most current status available.

Competitive Landscape & Strategic Developments

The competitive field is a blend of ASX-listed cultivators, global multi-national cannabis brands entering via distribution partnerships, and service-led players built around telehealth and dispensing. Differentiation now rests on three pillars: GMP certification depth, prescriber network access, and product-format breadth.

Notable Market Developments

• February 2023: Aurora partnered with MedReleaf Australia to launch the CraftPlant medical brand, broadening premium product availability for Australian patients.
• June 2023: The Legalise Cannabis Party introduced the Regulation of Personal Adult Use of Cannabis Bill in the Victorian, New South Wales and Western Australian parliaments, proposing possession of up to 50 grams and six plants per household alongside a national licensing scheme modelled on the Canadian framework.
• October 2023: The Australian Capital Territory formalised personal-use regulations permitting adults over 18 to possess up to 50 grams dried or 150 grams fresh cannabis.
• September 2024: Tilray Medical introduced EU-GMP-certified medical cannabis products in Australia, expanding clinician and patient access to internationally certified formats.
• February 2025: Dispensed announced plans to launch New Zealand operations using kiosks in pharmacies and clinics.
• March 2025: The Australian Greens highlighted an estimated USD 700 million in annual tax benefit from recreational product taxation, framing it as a potential funding stream for healthcare, education and infrastructure.

Strategic White-Space

• Standardised dosing formats. Capsules and metered oral sprays with pharmaceutical labelling conventions remain under-supplied relative to flower.
• Minor cannabinoid therapeutics. CBG, CBN and targeted terpene formulations lack scaled domestic supply.
• Rural and remote patient services. Telehealth has traction but fulfilment logistics in remote regions remain underserved.
• Real-world evidence generation. Producers with structured patient registries will convert clinical credibility into prescriber share.

Regional Attractiveness & Investment Opportunity Assessment

Demand and infrastructure are unevenly distributed across Australian jurisdictions, creating materially different investment profiles within a single national market.

The investment thesis concentrates on three vectors: GMP manufacturing capacity in New South Wales and Victoria, cultivation assets in Queensland and Western Australia, and export-facing distribution businesses servicing New Zealand, the United Kingdom and Germany. With an accelerated-case 2035 ceiling near USD 3.95 billion, the market's upside is most sensitive to federal policy movement rather than to incremental cultivation licence issuance.

Methodology & Data Integrity

This study combines primary interview programmes with official regulatory reporting, customs data and public health statistics. All figures are presented as our own first-party estimates derived from multi-level triangulation, and every dataset in this report is refreshed to the date of purchase. We estimate a data accuracy level of 85–90% across headline market sizing, with tighter confidence bands on medical segment values, where regulatory reporting granularity is highest, and wider bands on industrial hemp, where informal domestic transfer complicates measurement.